Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)

NCT04948749 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT04948749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04948749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)
Lead sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
July 2, 2021
Completion date
December 31, 2027
Enrollment
358 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

drug eluting stents (des), drug-eluting stent, icad - intracranial atherosclerotic disease, icas - intracranial atherosclerosis, medical treatment, stroke